Literature DB >> 12693439

Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders.

Kim A Weiss1, Thomas E Smith, James W Hull, A Courtney Piper, Jonathan D Huppert.   

Abstract

We investigated the course of adherence to medication recommendations in 162 patients with psychotic disorders in ambulatory treatment. Data were collected using the clinic's outcome assessment program, maximizing the generalizability of the study. Patients initially adherent to their medication regimens maintained their adherence for an average of 13.3 months. Patients initially nonadherent developed adherence after an average of 5.6 months of treatment. Demographic factors and illness history were unrelated to adherence. This study replicated previous findings of the concurrent association between adherence and global functioning level, substance use, and working alliance with therapist. Cox regression analyses revealed that working alliance, global functioning, and being prescribed clozapine predicted longer maintenance of adherence. Working alliance was the most significant and consistent predictor of adherence to medication recommendations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12693439     DOI: 10.1093/oxfordjournals.schbul.a006943

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  22 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Helping alliance and early dropout from psychiatric out-patient care: the influence of patient factors.

Authors:  Håkan Johansson; Mona Eklund
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-01-01       Impact factor: 4.328

3.  [Causes of non-compliance of patients who attend a community pharmacy in Granada].

Authors:  Mercedes Bueno Gómez; María Dolores Barrionuevo Sancho; Narjis Fikri Benbrahim; Emilio García-Jiménez
Journal:  Aten Primaria       Date:  2008-02       Impact factor: 1.137

4.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 5.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

Review 6.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

Review 7.  The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review.

Authors:  Laura Thompson; Rose McCabe
Journal:  BMC Psychiatry       Date:  2012-07-24       Impact factor: 3.630

8.  Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.

Authors:  Hong Liu-Seifert; Haya Ascher-Svanum; Olawale Osuntokun; Kai Yu Jen; Juan Carlos Gomez
Journal:  BMC Psychiatry       Date:  2011-05-17       Impact factor: 3.630

9.  Poor response to treatment: beyond medication.

Authors:  César Carvajal
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

10.  Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; Ron Landbloom; Marvin Swartz; Jeff Swanson
Journal:  BMC Psychiatry       Date:  2006-02-21       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.